Predictors of drug survival of biologic therapies in psoriasis patients
dc.contributor.buuauthor | Zorlu, Özge | |
dc.contributor.buuauthor | Bülbül Başkan, Emel | |
dc.contributor.buuauthor | Yazıcı, Serkan | |
dc.contributor.buuauthor | Sığırlı, Deniz | |
dc.contributor.buuauthor | Budak, Ferah | |
dc.contributor.buuauthor | Sarıcaoğlu, Hayriye | |
dc.contributor.buuauthor | Aydoğan, Kenan | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji ve Venereoloji Anabilim Dalı. | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı. | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı. | |
dc.contributor.orcid | 0000-0001-5555-130X | |
dc.contributor.orcid | 0000-0002-0144-3263 | |
dc.contributor.orcid | 0000-0001-7625-9148 | |
dc.contributor.researcherid | ABD-1191-2021 | |
dc.contributor.researcherid | AAH-1388-2021 | |
dc.contributor.researcherid | AAH-2459-2021 | |
dc.contributor.researcherid | AAA-7472-2021 | |
dc.contributor.researcherid | F-4657-2014 | |
dc.contributor.researcherid | DPU-8534-2022 | |
dc.contributor.researcherid | AAH-6216-2021 | |
dc.contributor.scopusid | 57203899392 | |
dc.contributor.scopusid | 6602518817 | |
dc.contributor.scopusid | 25925620000 | |
dc.contributor.scopusid | 24482063400 | |
dc.contributor.scopusid | 6701913697 | |
dc.contributor.scopusid | 6603722836 | |
dc.contributor.scopusid | 9739755800 | |
dc.date.accessioned | 2024-02-05T10:34:13Z | |
dc.date.available | 2024-02-05T10:34:13Z | |
dc.date.issued | 2022-01-02 | |
dc.description.abstract | Introduction: We aimed to investigate the clinical, immunological, and genetic factors affecting the response to anti-TNF alpha (tumor necrosis factor-alpha) and interleukin-12/23 therapies and drug survivals. Methods: A total of 180 patients were divided into two groups: 89 patients who used at least two biologic agents, with the initial biologic agent used less than 12 months (group A), and 91 biologic-naive patients who have been receiving a single biologic agent for more than 12 months (group B). ELISA (enzyme-linked immunosorbent assay) was used to analyze anti-drug antibodies (ADAs) in blood samples. Clinical data of the patients were retrospectively analyzed. HLA-SSO (sequence-specific oligonucleotide) Typing Kits were used for HLA-C typing. IBM SPSS v.21 was used for statistical analysis. Results: Infliximab had the longest drug survival as the first biologic agent in group A (p = .015). Etanercept had the lowest ADA count compared to the other anti-TNF agents (p = .001). HLA-Cw6 negativity, late-onset psoriasis, smoking and alcohol use were determined to be risk factors for treatment failure in group A. HLA-Cw6 was found to be associated with type I psoriasis (p = .000). Conclusions: Although our study is retrospective of a relatively low number of patients, this is a preliminary study focusing on two different patient populations based on therapy response. | en_US |
dc.identifier.citation | Zorlu, Ö. vd. (2020). "Predictors of drug survival of biologic therapies in psoriasis patients". Journal of Dermatological Treatment, 33(1), 437-442. | en_US |
dc.identifier.doi | https://doi.org/10.1080/09546634.2020.1763240 | |
dc.identifier.endpage | 442 | tr_TR |
dc.identifier.issn | 0954-6634 | |
dc.identifier.issn | 1471-1753 | |
dc.identifier.issue | 1 | tr_TR |
dc.identifier.pubmed | 32351141 | tr_TR |
dc.identifier.scopus | 2-s2.0-85084815890 | tr_TR |
dc.identifier.startpage | 437 | tr_TR |
dc.identifier.uri | https://www.tandfonline.com/doi/full/10.1080/09546634.2020.1763240 | |
dc.identifier.uri | https://hdl.handle.net/11452/39514 | |
dc.identifier.volume | 33 | tr_TR |
dc.identifier.wos | 000534285400001 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Taylor & Francis Ltd | en_US |
dc.relation.journal | Journal of Dermatological Treatment | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Dermatology | en_US |
dc.subject | Anti-TNF | en_US |
dc.subject | Biologics | en_US |
dc.subject | HLA-Cw6 | en_US |
dc.subject | Psoriasis | en_US |
dc.subject | Clinical-response | en_US |
dc.subject | Observational cohort | en_US |
dc.subject | British association | en_US |
dc.subject | Ustekinumab | en_US |
dc.subject | Polymorphisms | en_US |
dc.subject | Etanercept | en_US |
dc.subject | Adalimumab | en_US |
dc.subject | HLA-C-asterisk-06 | en_US |
dc.subject | Antibodies | en_US |
dc.subject | Allele | en_US |
dc.subject.emtree | Adalimumab | en_US |
dc.subject.emtree | Biological product | en_US |
dc.subject.emtree | Drug antibody | en_US |
dc.subject.emtree | Etanercept | en_US |
dc.subject.emtree | HLA C antigen | en_US |
dc.subject.emtree | Infliximab | en_US |
dc.subject.emtree | Interleukin 12 | en_US |
dc.subject.emtree | Interleukin 23 | en_US |
dc.subject.emtree | Ustekinumab | en_US |
dc.subject.emtree | Adalimumab | en_US |
dc.subject.emtree | Drug | en_US |
dc.subject.emtree | Etanercept | en_US |
dc.subject.emtree | Infliximab | en_US |
dc.subject.emtree | Tumor necrosis factor inhibitor | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Alcohol consumption | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Biological therapy | en_US |
dc.subject.emtree | Blood sampling | en_US |
dc.subject.emtree | Data analysis software | en_US |
dc.subject.emtree | Disease severity | en_US |
dc.subject.emtree | Enzyme linked immunosorbent assay | en_US |
dc.subject.emtree | Family history | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Gene frequency | en_US |
dc.subject.emtree | Heredity | en_US |
dc.subject.emtree | HLA system | en_US |
dc.subject.emtree | HLA typing | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Late onset disorder | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Mail psoriasis | en_US |
dc.subject.emtree | Psoriasis | en_US |
dc.subject.emtree | Psoriasis vulgaris | en_US |
dc.subject.emtree | Psoriatic arthritis | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Risk factor | en_US |
dc.subject.emtree | Smoking | en_US |
dc.subject.emtree | Survival prediction | en_US |
dc.subject.emtree | Treatment failure | en_US |
dc.subject.emtree | Treatment response | en_US |
dc.subject.emtree | Biological therapy | en_US |
dc.subject.mesh | Adalimumab | en_US |
dc.subject.mesh | Biological therapy | en_US |
dc.subject.mesh | Etanercept | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Infliximab | en_US |
dc.subject.mesh | Pharmaceutical preparations | en_US |
dc.subject.mesh | Psoriasis | en_US |
dc.subject.mesh | Retrospective studies | en_US |
dc.subject.mesh | Tumor necrosis factor inhibitors | en_US |
dc.subject.scopus | Pustulosis Palmoplantaris; Secukinumab; Nail Diseases | en_US |
dc.subject.wos | Dermatology | en_US |
dc.title | Predictors of drug survival of biologic therapies in psoriasis patients | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q2 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: